Changes to Novasep Governance
News Oct 03, 2012
Novasep has announced the appointment of Roger-Marc Nicoud, founder and CEO, as non-executive chairman of the board, effective on October 1st, 2012.
Patrick Glaser, who has been in charge of the Novasep Synthesis division since May 2010, becomes president and CEO, effective on October 1st, 2012.
Bolstered by its new shareholder structure since the completion of its refinancing, Novasep is now in a position to accelerate the development of its activities in France and internationally and to enter into a new phase of growth and investments.
In this regard, Novasep shareholders and Roger-Marc Nicoud have commonly decided to bring about change in the firm's governance by appointing Patrick Glaser, head of the Novasep Synthesis division, as the new President and CEO, while Roger-Marc Nicoud becomes non-executive chairman of the board.
Roger-Marc Nicoud, founder and non-executive chairman of the board of Novasep, said: "As the founder of Novasep and having managed the firm for over 20 years, I think it is the right time for a change in the company's leadership. In a short period of time, our new shareholders have demonstrated their commitment to support the growth of our business by endorsing significant investment, so that we are in a position to take full advantage of our unique leadership in purification technologies. I have been working with Patrick for more than two years and during that time he has successfully grown our chemical activities. I am happy to see him as my successor. With recent sizeable commercial successes, committed shareholders and talented management, Novasep is in good hands. As non-executive chairman of the board, I will work alongside the other board members to ensure a smooth transition. I will continue to share my scientific expertise at board level, in the interests of our customers, shareholders and employees."
Aviva Shneider, former non-executive chairman of the board of Novasep and representative of the shareholders, declared: "On behalf of the board, I want to thank Roger-Marc for the fantastic achievements of a long tenure as the founder and CEO of Novasep. I am pleased that, as my successor as non-executive chairman of the board, he will continue to contribute his unprecedented experience and scientific skills for the benefit of all Novasep's stakeholders. As the representative to the shareholders, I would also like to take this opportunity to reaffirm our commitment to support the growth and expansion of the company and our excitement about its capabilities and prospects."
Thomas Devedjian, director - executive board member of Fonds Stratégique d'Investissement (FSI), declared: "We would like to thank Roger-Marc Nicoud for his very strong involvement in the recovery of the company through the recent refinancing and different promising projects such as the new anti-cancer molecules production capacities in Le Mans. We are thus very confident in the future development of Novasep."
One in Five Materials Chemistry Papers May be Wrong, Study SuggestsNews
The replicability of results from scientific studies has become a major source of concern in the research community, particularly in the social sciences and biomedical sciences. A new study that compared the results reported in thousands of papers published about the properties of metal organic framework (MOF) materials – which are prominent candidates for carbon dioxide adsorption and other separations – suggests the replicability problem should be a concern for materials researchers, too.READ MORE
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
Salmonella Cases No Longer Declining in the EUNews
The declining trend of salmonellosis cases in the EU has levelled off according to the annual report on zoonotic diseases. Cases of Salmonella Enteritidis acquired in the EU have increased in humans by 3% since 2014 and in laying hens, the prevalence increased from 0.7% to 1.21% over the same period.